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Hypercoagulability resulting from opposite effects
of lupus anticoagulants is associated strongly
with thrombotic risk
Interference of antiphospholipid antibodies (aPL)
with coagulation was investigated in 40 aPL-
patients (24 with thrombosis) using thrombogra-
phy. Impairment of the activated protein C antico-
agulant pathway was partially offset by the genuine
anticoagulant effect. The net result, a procoagulant
phenotype, was associated with a 7-fold increased
risk of thrombosis in aPL-patients.
Haematologica 2007; 92:5: 714-715
Antiphospholipid antibodies (aPL) are associated with
thrombosis and/or pregnancy morbidity in the setting of
the antiphospholipid syndrome (APS).1 Some aPL-posi-
tive patients remain asymptomatic suggesting that
improved assessment of the thrombotic risk is still
required. While aPL-induced inhibition of thrombin for-
mation has been reported,2,3 acquired activated protein C
(APC) resistance and is thought to be the main cause of
aPL-associated thrombosis.2,4 However, this remains the
subject of debate.4-6 Previously, we demonstrated that
thrombography could confirm both the extent of the
lupus anticoagulant (LA) effect and APC resistance of
thrombin generation.7 Given the range of laboratory aPL
characteristics and the complexity of thrombin formation
and inhibition, composite interference of immune com-
plexes on pro- and anti-coagulant complexes may deter-
mine the overall result. We studied 40 persistently aPL-
positive patients and 19 aPL-negative healthy controls.
The study aimed to investigate if the net in vitro pheno-
type is hypercoagulability, and to determine whether
total generated thrombin activity, given the two opposite
effects of aPL, is associated with an increased risk of
thrombosis, to determine whether total generated throm-
bin activity is associated with an increased risk of throm-
bosis given the two opposite effects of aPL.
Twenty-four of the aPL-positive patients had experi-
enced thrombosis but were not treated with anticoagu-
lants for medical reasons independent of this study. Two
patients were undergoing bridging therapy with low-
molecular-weight heparin. In these 2 cases, plasmas were
obtained when heparin levels were undetectable. Patient
characteristics are summarized in Table 1. Thrombin con-
centration over time in blood specimens stimulated with
phospholipid-free tissue factor was recorded in the
absence or the presence of APC. Total generated throm-
bin activity was quantified by the endogenous thrombin
potential (ETP) as previously described.8
On average, there was no statistical difference in ETP
without APC (ETP0) between patients and controls
whereas ETP in the presence of any APC concentration
was significantly higher (p<0.005) for patients than for
controls (mean increase of 1.7-fold: see Figure 1A).
Overall response to APC was evaluated using APC con-
centration at half the ETP0 value (IC50 APC).8 Analysis
showed significantly higher values for patients compared
with controls (32.0±3.4 vs 9.1±0.9 nM, p<0.0001). In
contrast, ETP0 was lower for LA-positive patients (n=23)
than for LA-negative patients (1227±65 vs 1680±131
nM.min, p<0.005) and the respective IC50-APC was high-
er (42.2±4.6 vs 18.2±2.7 nM, p<0.001) (see Figure 1B).
Overall, APC inhibition was greater (elevated ETP in
presence of APC) than prothrombin activation (low
ETP0), resulting in a net procoagulant phenotype. This
may be due to differences in membrane requirements and
binding kinetics between pro- and anti-coagulant factors.
Patients with and without thrombosis were compared to
examine whether APC resistance alone may favor throm-
bosis. IC50-APC was higher in APS-patients than in
asymptomatic aPL-positive patients (37.2±4.6 vs
24.1±4.6 nM, p=0.05). However, odds ratio (OR) of
thrombosis associated with IC50-APC did not reach signif-
icance (Figure 1C).
The extent to which a phenotype integrates the two
opposite effects of LA is associated with thrombosis was
assessed by using two combined thrombographic param-
eters, APC sensitivity ratio (APCsr) and ETP0×IC50-APC.
In fact, APCsr based on ETP ratios was reported to be
associated with thrombosis elsewhere previously.9 We
observed a negative correlation between APCsr and ETP0
and a positive one between APCsr and ETP in the pres-
ence of 13.9 nM added APC. Seventeen of the 24 APS-
patients displayed APCsr >99th percentile compared to 5
of the 16 asymptomatic aPL-positive patients (p=0.02). A
significantly elevated thrombotic risk was therefore
found for APCsr values exceeding the 99th percentile, OR
was 5.34; 95% CI=1.35-21.1 (Figure 1C). The use of ETP
ratios is limited by the fact that the response to APC is
investigated with only one arbitrary concentration of
APC. Considering that IC50-APC globally assessed the
response to APC and had to be combined with ETP0, we
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Table 1. Patients’ characteristics.
APS- APS+
(n=16) (n=24)
Men/Women 3/13 8/16
Age, years 43±4 41±3
(23–69) (21–76)
aPL-associated thrombocytopenia (platelet count <100 G/L)
(blood platelet count, G/L) 0 1 severe
(30)
SLE or lupus-like 6 8
Primary APS − 16
Thromboembolic events
Vascular thrombosis − 21
Pregnancy morbidity − 4
Catastrophic APS − 2
Laboratory criteria
Category I (more than one laboratory 5 13
criteria present)
Category IIa (lupus anticoagulants 3 4
present alone)
Category IIb (anti-cardiolipin present 8 7
alone)
Continuous variables denoted as mean±SEM (range), categorical variables as
number. SLE indicates systemic lupus erythematosus; APS, antiphospholipid
syndrome; APS-, asymptomatic aPL-positive patients, APS+, patients with APS;
- not applicable. Categories I, IIa and IIb refer to classification accorded
to Sydney criteria. Lupus anticoagulant testing was in agreement with the
International Society on Thrombosis and Haemostasis recommendations,
taking into account the Sydney revision. Anticardiolipin and anti-β2-glycoprotein
I antibodies were detected by home-based ELISA with cut-off levels locally
defined by the method of percentiles with more than 50 healthy volunteers.
Antibody values were distributed up to 35-fold, 70-fold, 5-fold and 22-fold the
cut-off value for IgG anticardiolipin, IgG anti-β2-glycoprotein I, IgM
anti-cardiolipin and IgM anti-β2-glycoprotein I respectively.
 
used their arithmetic product and thus confirmed that a
net procoagulant phenotype was associated with an
increased risk of thrombosis, OR was 7.29; 95% CI=1.74-
30.6 (Figure 1C). In contrast, OR of thrombosis associat-
ed with plasma markers of in vivo activation of coagula-
tion (F1+2 and D-dimers) was not significant. This had
been previously reported for patients with inherited
thrombophilia.10 Clotting system reactivity is assessed by
the amount of thrombin that can be formed in vitro in
response to a defined stimulus, while plasma markers
reflecting thrombin generation in vivo depend on both
this reactivity and intermittent triggers of different inten-
sities.
In conclusion, changes in sensitivity of thrombin activ-
ity to APC, taking into account its modulation by the
genuine anticoagulant effect of aPL, is associated with an
increased risk of thrombosis in aPL-positive patients.
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Figure 1. Association of the in vitro phenotype of the clotting sys-
tem with definite antiphospholipid syndrome. A. Values obtained
with platelet-rich plasma (PRP) of the 19 controls (open symbols)
and PRP of the 40 patients (closed symbols). For each subject,
measurements are means of triplicate. * p<0.005 compared with
controls. B. Values obtained with PRP of the 23 patients with
lupus anticoagulants (dark grey symbols) and PRP of the 17
patients without lupus anticoagulants (light grey symbols). C.
Association of the in vitro phenotype or in vivo activation of coag-
ulation and risk of thrombosis when comparing patients with
(APS+) and without (APS–) thrombosis. Results are expressed as
odds ratios with accompanying 95%CI for a cut-off level set at the
99th percentile of the control values. The markers of in vivo acti-
vation of coagulation were F1 + 2 fragments (thrombin formation)
and D-dimers (degradation products of fibrin formed by throm-
bin). ETP0, ETP value without APC; IC50-APC, APC concentration
reducing ETP0 by 50%; APCsr, APC sensitivity ratio: ETP in pres-
ence of 13.9 nM APC/ETP0.
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